THBD and Sepsis: However, in an observational study based on registry data conducted in Japan (where thrombomodulin is a registered drug), unsupervised clustering analysis using a set of readily available coagulation parameters identified a subgroup of patients with a high likelihood of survival benefit, showing treatment heterogeneity even within a cohort of patients with sepsis-associated coagulopathy [65].